Comparisons have been made between Prima and Dendreon as they are both using similar science technology to treat cancer(s).
I thought it would be interesting to review Dendreon's journey over the years to where it is today and use this as a possible template to project where Prima may be in 2/3 years.
Dendreon
Dec 2005 - public offering 11.5 million shares @ $4.50
June 2006 - pivotal phase 3 study results
Nov 2006 - submits complete FDA application
Nov 2006- institutional offering raises $45m ($4.50/share)
Mar 2007 - FDA committee reviews Provenge application (share price hits $20)
May 2007 - FDA requests additional clinical data (share price drops to circa $7.00)
June 2007- further capital raising (convertible $8.75 notes) $75m.(to fund additional trials)
Oct 2007 - $130m committed equity financing facility (manufacturing Provenge)
- target enrollment completed - 500 patients
Mar 2008 - FDA agrees to amend special protocol assessment for Phase 3 impact study.
April 2009 - Dendreon announces 'Provenge significantly prolongs survival in men with advanced prostrate cancer'. Share price rises to $22.00
May 2009 - common stock offering, 11 million shares @ $19.50 (manufacturing facilities).
April 2010 - FDA approval. Shares peak $50 !
Dendreon effectively 'lost' 2 years due to FDA requesting more clinical data. I am sure Prima/FDA will ensure that pre quantified/ qualified measuring endpoints are not ambiguous, thus on the premise that phase 3 trials are successful, should considerably speed up Cvacs time to market, compared to Provenge.
Prima is now at the serious pointy end - pivotal phase 3 trials (and phase 2b - 60 patients). 800 patients to be enrolled. Interim data Q4 - 2012/Q1 - 2013. Final data Q4 - 2013/Q1 2014.
Simple valuation comparison Prima v Dendreon.
Same development stage - Phase 3 recruitment/fully funded.
Dendreon - Initial public offering -$4.50 (fully funded for first p3 trials) . Todays share price $45.00. 10x growth.
Prima - commencement of p3 enrollment - share price $0.30.
Assuming min 10x valuation (FDA approval assumed) - $3.00.
Factor in additional cancer vaccines/products and 'significantly' lower capex (compared to Dendreon at same stage), then the upside to this simple valuation is significant.
Obviously only my humble opinion. Apologies if I bored you to sleep (that is if you managed to get this far).
PS. TOU'd you guys last night for 'blatant reminiscing'. Well done mod's for allowing such nonsense!
- Forums
- ASX - By Stock
- meanwhile....
Comparisons have been made between Prima and Dendreon as they...
-
- There are more pages in this discussion • 62 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IMM (ASX) to my watchlist
|
|||||
Last
40.5¢ |
Change
0.040(11.0%) |
Mkt cap ! $588.3M |
Open | High | Low | Value | Volume |
37.0¢ | 40.5¢ | 36.8¢ | $1.822M | 4.681M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 19739 | 39.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
40.5¢ | 45420 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 19739 | 0.390 |
2 | 28000 | 0.385 |
6 | 50173 | 0.380 |
2 | 38500 | 0.375 |
3 | 82324 | 0.370 |
Price($) | Vol. | No. |
---|---|---|
0.410 | 183750 | 2 |
0.415 | 15231 | 2 |
0.420 | 452907 | 6 |
0.430 | 38735 | 2 |
0.440 | 12636 | 1 |
Last trade - 16.10pm 30/08/2024 (20 minute delay) ? |
Featured News
IMM (ASX) Chart |
The Watchlist
CCO
THE CALMER CO INTERNATIONAL LIMITED
Anthony Noble, MD & CEO
Anthony Noble
MD & CEO
Previous Video
Next Video
SPONSORED BY The Market Online